{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:05:03Z","timestamp":1788822303913,"version":"build-2803163510"},"reference-count":70,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Background\/Objectives: The increasing use of immune checkpoint inhibitors (ICIs) in cancer treatment has led to a rise in immune-related adverse events (irAEs), including pancreatic injury. While current guidelines suggest that baseline monitoring of amylase and lipase levels is not necessary, it remains common in clinical settings, leading to confusion regarding their interpretation and management. This practice may lead to confusion, especially when patients exhibit isolated mild elevations of amylase and lipase, which may not always correlate with clinical pancreatitis. In contrast, significant elevations in these enzymes warrant further investigation, including imaging to assess the presence of pancreatitis. Methods: This review aims to provide a clearer framework for clinicians in managing ICI-induced pancreatic injury, promoting consistency in practice, and improving patient outcomes by reducing unnecessary interruptions to ICI therapy. Results: It is critical to distinguish between the severity of pancreatitis to guide management. Conclusions: Considering the expected rise in the use of immune ICIs, it is crucial to increase awareness about the potential for pancreatic injury associated with these treatments.<\/jats:p>","DOI":"10.3390\/metabo15060385","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T05:11:49Z","timestamp":1749532309000},"page":"385","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Investigating Immune Checkpoint Inhibitor-Induced Pancreatic Injury: When to Discontinue Cancer Therapy"],"prefix":"10.3390","volume":"15","author":[{"given":"Enrico Celestino","family":"Nista","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences, Universit\u00e0 Cattolica Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Sofia","family":"De Lucia","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Universit\u00e0 Cattolica Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7015-3395","authenticated-orcid":false,"given":"Sebastiano","family":"Archilei","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Universit\u00e0 Cattolica Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0511-0954","authenticated-orcid":false,"given":"Jacopo","family":"Iaccarino","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Universit\u00e0 Cattolica Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Piccirilli","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Universit\u00e0 Cattolica Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Nicoletti","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Universit\u00e0 Cattolica Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Saviano","sequence":"additional","affiliation":[{"name":"Department of Emergency, Anesthesiological, and Reanimation Sciences, Universit\u00e0 Cattolica Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6230-1779","authenticated-orcid":false,"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Universit\u00e0 Cattolica Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8953-0707","authenticated-orcid":false,"given":"Veronica","family":"Ojetti","sequence":"additional","affiliation":[{"name":"San Carlo di Nancy GVM Care and Research, Department of Internal Medicine, UniCamillus International University, 00131 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/ITT.S126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: A short review","volume":"6","author":"Yoest","year":"2017","journal-title":"Immunotargets Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clim.2014.04.010","article-title":"Programmed death-1 pathway in cancer and autoimmunity","volume":"153","author":"Pedoeem","year":"2014","journal-title":"Clin. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijid.2017.01.028","article-title":"Anti-PD-1\/PD-L1 therapy for infectious diseases: Learning from the cancer paradigm","volume":"56","author":"Rao","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.7150\/jca.8167","article-title":"PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases","volume":"5","author":"Jilaveanu","year":"2014","journal-title":"J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: A moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Meng, L., Collier, K.A., Wang, P., Li, Z., Monk, P., Mortazavi, A., Hu, Z., Spakowicz, D., Zheng, L., and Yang, Y. (2023). Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma. Cells, 13.","DOI":"10.3390\/cells13010034"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors\u2014A systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/ibd\/izad229","article-title":"Focus on Immune Checkpoint Inhibitors-Related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach","volume":"30","author":"Petito","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury","volume":"7","author":"Tang","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.pan.2019.04.015","article-title":"Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis","volume":"19","author":"George","year":"2019","journal-title":"Pancreatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e00667","DOI":"10.14309\/ctg.0000000000000667","article-title":"Incidence of Pancreatic Injury and Pancreatitis in Patients Treated With Immune Checkpoint Inhibitors","volume":"15","author":"Hori","year":"2024","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_18","first-page":"90","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE\u2014Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies","volume":"112","author":"Santana","year":"2021","journal-title":"Actas Dermosifiliogr."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhang, T., Wang, Y., Shi, C., Liu, X., Lv, S., Wang, X., and Li, W. (2022). Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.955701"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1027323","DOI":"10.1155\/2018\/1027323","article-title":"Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis","volume":"2018","author":"Su","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S1470-2045(21)00333-8","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: A systematic review and meta-analysis","volume":"22","author":"Zhou","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/CMR.0000000000000611","article-title":"Immune-related pancreatitis associated with checkpoint blockade in melanoma","volume":"29","author":"Kohlmann","year":"2019","journal-title":"Melanoma Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"107498","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"Chen","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1. 2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00535-024-02083-1","article-title":"Pancreatic injury in patients treated with immune checkpoint inhibitors: A retrospective multicenter study","volume":"59","author":"Nagao","year":"2024","journal-title":"J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/mi.2016.101","article-title":"Immunopathogenesis of pancreatitis","volume":"10","author":"Watanabe","year":"2017","journal-title":"Mucosal Immunol."},{"key":"ref_29","first-page":"e68043","article-title":"Immune Checkpoint Inhibitors in Cancer Treatment and Incidence of Pancreatitis","volume":"16","author":"Nwankwo","year":"2024","journal-title":"Cureus"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","article-title":"Immune-related toxicities of checkpoint inhibitors: Mechanisms and mitigation strategies","volume":"21","author":"Sullivan","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Poto, R., Troiani, T., Criscuolo, G., Marone, G., Ciardiello, F., Tocchetti, C.G., and Varricchi, G. (2022). Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.804597"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/rheumatology\/key358","article-title":"Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis","volume":"58","author":"Cappelli","year":"2019","journal-title":"Rheumatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dme.14050","article-title":"Immune checkpoint inhibitor-induced Type 1 diabetes: A systematic review and meta-analysis","volume":"36","author":"Akturk","year":"2019","journal-title":"Diabet. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Liu, Y., Zhang, H., Zhou, L., Li, W., Yang, L., Li, W., Li, K., and Liu, X. (2021). Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.627612"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00262-008-0642-y","article-title":"Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: Clinical and immunological evidence from three patient cases","volume":"58","author":"Danielli","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Chen, F., Vyas, M., Gosse, M., Deshpande, V., and Rosenbaum, M.W. (2025). Clinicopathologic Characteristics of Immune Checkpoint Inhibitor-related Pancreatitis. Am. J. Surg. Pathol.","DOI":"10.1097\/PAS.0000000000002398"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Nakano, R., Shiomi, H., Fujiwara, A., Yoshihara, K., Yoshioka, R., Kawata, S., Ota, S., Yuri, Y., Takashima, T., and Aizawa, N. (2022). Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings. Healthcare, 10.","DOI":"10.3390\/healthcare10050763"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2217\/imt-2017-0126","article-title":"Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy","volume":"10","author":"Prasanna","year":"2018","journal-title":"Immunotherapy"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"109250","DOI":"10.1016\/j.ejrad.2020.109250","article-title":"Imaging findings of immune checkpoint inhibitor associated pancreatitis","volume":"131","author":"Das","year":"2020","journal-title":"Eur. J. Radiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/1759-7714.13990","article-title":"Clinical-radiological characteristics and intestinal microbiota in patients with pancreatic immune-related adverse events","volume":"12","author":"Tan","year":"2021","journal-title":"Thorac. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2018.02.006","article-title":"Focal immune-related pancreatitis occurring after treatment with programmed cell death 1 inhibitors: A distinct form of autoimmune pancreatitis?","volume":"95","author":"Capurso","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1148\/radiol.2019191603","article-title":"Nivolumab-induced Pancreatitis: An Immune-related Adverse Event","volume":"293","author":"Saito","year":"2019","journal-title":"Radiology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/jgh.14620","article-title":"Nivolumab-related pancreatitis with autoimmune pancreatitis-like imaging features","volume":"34","author":"Tanaka","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s12328-021-01499-z","article-title":"Pembrolizumab-induced autoimmune side effects of colon and pancreas in a patient with lung cancer","volume":"14","author":"Ofuji","year":"2021","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1097\/MPA.0000000000001756","article-title":"Pancreatic Atrophy in Nivolumab-Associated Pancreatitis Mimics Autoimmune Pancreatitis","volume":"50","author":"Janssens","year":"2021","journal-title":"Pancreas"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN Guidelines\u00ae Insights: Management of Immunotherapy-Related Toxicities, Version 2. 2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"831","DOI":"10.6004\/jnccn.2023.7034","article-title":"Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy","volume":"21","author":"Townsend","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.gastha.2023.11.020","article-title":"Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Clinical and Radiological Profile and Response to Steroids","volume":"3","author":"Thomas","year":"2023","journal-title":"Gastro Hep Adv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"114028","DOI":"10.1016\/j.ejca.2024.114028","article-title":"Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"203","author":"Ruf","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10637-024-01452-0","article-title":"Clinical characteristics, treatment and outcome of pembrolizumab-induced acute pancreatitis","volume":"42","author":"Luo","year":"2024","journal-title":"Investig. New Drugs"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12328-022-01731-4","article-title":"Immune-related colitis and pancreatitis treated with infliximab","volume":"16","author":"Ohwada","year":"2023","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/CJI.0000000000000472","article-title":"Immune Checkpoint Inhibitor-related Pancreatitis: A Case Series, Review of the Literature and an Expert Opinion","volume":"46","author":"Kramer","year":"2023","journal-title":"J. Immunother."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Santoro, A., Masini, S., Cavina, R., Tronconi, M.C., and De Vincenzo, F. (2023). Rituximab in steroid-refractory immune-related pancreatitis: A case report. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1205720"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41698-023-00380-1","article-title":"Immunosuppression for immune-related adverse events during checkpoint inhibition: An intricate balance","volume":"7","author":"Verheijden","year":"2023","journal-title":"NPJ Precis. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Parvathareddy, V., Selamet, U., Sen, A.A., Mamlouk, O., Song, J., Page, V.D., Abdelrahim, M., Diab, A., Abdel-Wahab, N., and Abudayyeh, A. (2023). Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response. Cancers, 15.","DOI":"10.3390\/cancers15215181"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11894-023-00885-6","article-title":"Immune Checkpoint Inhibitor-Induced (Type 3) Autoimmune Pancreatitis","volume":"25","author":"Chari","year":"2023","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/oncolo\/oyad150","article-title":"Exocrine Pancreatic Insufficiency Induced by Immune Checkpoint Inhibitors","volume":"28","author":"Satish","year":"2023","journal-title":"Oncologist"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejca.2017.08.024","article-title":"Diarrhoea during checkpoint blockade, not always colitis","volume":"87","author":"Koldenhof","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_63","first-page":"e26596","article-title":"Pembrolizumab-Induced Pancreatic Exocrine Insufficiency Complicated by Severe Hepatic Steatosis","volume":"14","author":"Hong","year":"2022","journal-title":"Cureus"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"110776","DOI":"10.1016\/j.diabres.2023.110776","article-title":"Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy\u2014A comprehensive cancer center experience","volume":"202","author":"Zhang","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Lee, C.L., Riya, I.J., Piya, I.J., Muniz, T.P., Butler, M.O., and Saibil, S.D. (2025). Immune Checkpoint Inhibitor-Induced Pancreatic Injury (ICI-PI) in Adult Cancer Patients: A Systematic Review and Meta-Analysis. Cancers, 17.","DOI":"10.3390\/cancers17071080"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00592-019-01402-w","article-title":"The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors","volume":"56","author":"Marchand","year":"2019","journal-title":"Acta Diabetol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s12020-024-04050-5","article-title":"Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus","volume":"87","author":"Kani","year":"2025","journal-title":"Endocrine"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1097\/MEG.0000000000001852","article-title":"Severe fistulizing pancreatitis in a patient with Merkel cell carcinoma treated with avelumab","volume":"32","author":"Khurana","year":"2020","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jaccao.2022.09.004","article-title":"Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Tan","year":"2022","journal-title":"JACC CardioOncol."},{"key":"ref_70","first-page":"49","article-title":"Management of Acute Pancreatitis Associated With Checkpoint Inhibitors","volume":"11","author":"Rogers","year":"2020","journal-title":"J. Adv. Pract. Oncol."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/15\/6\/385\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:49:13Z","timestamp":1760032153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/15\/6\/385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":70,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["metabo15060385"],"URL":"https:\/\/doi.org\/10.3390\/metabo15060385","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]}}}